Abstract
Introduction: Social contact patterns significantly influence the transmission dynamics of respiratory pathogens. Previous surveys have quantified human social contact patterns, yielding heterogeneous results across different locations. However, significant gaps remain in understanding social contact patterns in rural areas of China. Methods: We conducted a pioneering study to quantify social contact patterns in Anhua County, Hunan Province, China, from June to October 2021, when there were minimal coronavirus disease related restrictions in the area. Additionally, we simulated the epidemics under different assumptions regarding the relative transmission risks of various contact types (e.g., indoor versus outdoor, and physical versus non-physical). Results: Participants reported an average of 12.0 contacts per day (95% confidence interval: 11.3-12.6), with a significantly higher number of indoor contacts compared to outdoor contacts. The number of contacts was associated with various socio-demographic characteristics, including age, education level, income, household size, and travel patterns. Contact patterns were assortative by age and varied based on the type of contact (e.g., physical versus non-physical). The reproduction number, daily incidence, and infection attack rate of simulated epidemics were remarkably stable. Discussion: We found many intergenerational households and contacts that pose challenges in preventing and controlling infections among the elderly in rural China. Our study also underscores the importance of integrating various types of contact pattern data into epidemiological models and provides guidance to public health authorities and other major stakeholders in preparing and responding to infectious disease threats in rural China.
Competing Interest Statement
HY has received research funding from Sanofi Pasteur, GlaxoSmithKline, Shanghai Roche Pharmaceutical Company, Shenzhen Sanofi Pasteur Biological Products Co., Ltd and SINOVAC Biotech Ltd.
Funding Statement
This study was funded by the Shanghai Municipal Science and Technology Major Project (ZD2021CY001), NIHR Global Health Research Group in Evidence to Policy pathway for Immunisation in China (EPICs; 16/137/109), the Key Program of the National Natural Science Foundation of China (82130093), the National Natural Science Foundation of China (92369118 and 82304202), and Shanghai Rising-Star Program (No. 22QA1402300).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All procedures performed in this study were approved by the ethics committees of the School of Public Health at Fudan University, Shanghai, China (Ref: 2020-11-0857-S2) and the London School of Hygiene and Tropical Medicine, London, UK (Ref: 22684-04), and were following the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study (from a guardian if the participant was under 6 years old; from both a guardian and the study participant if the participant was 7-17 years old; from the participant if the participant was 18 years or above).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All individual-level data will be made available upon acceptance of the manuscript.
